CDK12: A Potent Target and Biomarker for Human Cancer Therapy

被引:41
|
作者
Liang, Shujing [1 ,2 ,3 ]
Hu, Lifang [1 ,2 ,3 ]
Wu, Zixiang [1 ,2 ,3 ]
Chen, Zhihao [1 ,2 ,3 ]
Liu, Shuyu [1 ,2 ,3 ]
Xu, Xia [1 ,2 ,3 ]
Qian, Airong [1 ,2 ,3 ]
机构
[1] Northwestern Polytech Univ, Lab Bone Metab, Xian Key Lab Special Med & Hlth Engn, Xian 710072, Peoples R China
[2] Northwestern Polytech Univ, Key Lab Space Biosci & Biotechnol, Res Ctr Special Med & Hlth Syst Engn, Xian 710072, Peoples R China
[3] Northwestern Polytech Univ, NPU UAB Joint Lab Bone Metab, Sch Life Sci, Xian 710072, Peoples R China
基金
中国国家自然科学基金;
关键词
cyclin-dependent kinase 12; gene transcription; cell cycle; cell proliferation; DNA damage response; cancer therapy; CYCLIN-DEPENDENT-KINASES; DNA-DAMAGE RESPONSE; PROLINE-RICH MOTIFS; PRE-MESSENGER-RNA; C-TERMINAL DOMAIN; SH3; DOMAIN; CELL-CYCLE; BREAST-CANCER; PROTEIN; TRANSCRIPTION;
D O I
10.3390/cells9061483
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Cyclin-dependent kinases (CDKs) are a group of serine/threonine protein kinases and play crucial roles in various cellular processes by regulating cell cycle and gene transcription. Cyclin-dependent kinase 12 (CDK12) is an important transcription-associated CDK. It shows versatile roles in regulating gene transcription, RNA splicing, translation, DNA damage response (DDR), cell cycle progression and cell proliferation. Recently, increasing evidence demonstrates the important role ofCDK12in various human cancers, illustrating it as both a biomarker of cancer and a potential target for cancer therapy. Here, we summarize the current knowledge ofCDK12, and review the research advances ofCDK12 ' s biological functions, especially its role in human cancers and as a potential target and biomarker for cancer therapy.
引用
收藏
页码:1 / 15
页数:15
相关论文
共 50 条
  • [41] CDK12 Activity-Dependent Phosphorylation Events in Human Cells
    Bartkowiak, Bartlomiej
    Yan, Christopher M.
    Soderblom, Erik J.
    Greenleaf, Arno L.
    BIOMOLECULES, 2019, 9 (10)
  • [42] The promise and current status of CDK12/13 inhibition for the treatment of cancer
    Tadesse, Solomon
    Duckett, Derek R.
    Monastyrskyi, Andrii
    FUTURE MEDICINAL CHEMISTRY, 2021, 13 (02) : 117 - 141
  • [43] CDK12 is hyperactivated and a synthetic-lethal target in BRAF-mutated melanoma
    Thibault Houles
    Geneviève Lavoie
    Sami Nourreddine
    Winnie Cheung
    Éric Vaillancourt-Jean
    Célia M. Guérin
    Mathieu Bouttier
    Benoit Grondin
    Sichun Lin
    Marc K. Saba-El-Leil
    Stephane Angers
    Sylvain Meloche
    Philippe P. Roux
    Nature Communications, 13
  • [44] CDK12 is hyperactivated and a synthetic-lethal target in BRAF-mutated melanoma
    Houles, Thibault
    Lavoie, Genevieve
    Nourreddine, Sami
    Cheung, Winnie
    Vaillancourt-Jean, Eric
    Guerin, Celia M.
    Bouttier, Mathieu
    Grondin, Benoit
    Lin, Sichun
    Saba-El-Leil, Marc K.
    Angers, Stephane
    Meloche, Sylvain
    Roux, Philippe P.
    NATURE COMMUNICATIONS, 2022, 13 (01)
  • [45] The combination of CDK12 KO and TP53 KD may not mimic aggressive phenotype seen in clinical CDK12 LOF prostate cancer.
    Kamiyama, Yuki
    Fukui, Tomohiro
    Sunada, Takuro
    Kimura, Hiroko
    Goto, Takayuki
    Kobayashi, Takashi
    Akamatsu, Shusuke
    CANCER SCIENCE, 2022, 113 : 1594 - 1594
  • [46] A patent and literature review of CDK12 inhibitors
    Tang, Ruijun
    Liu, Jing
    Li, Shuyao
    Zhang, Junjie
    Yu, Chunhong
    Liu, Honglu
    Chen, Fang
    Lv, Lu
    Zhang, Qian
    Yuan, Kai
    Shao, Hao
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2022, 32 (10) : 1055 - 1065
  • [47] Human CDK12 and CDK13, multi-tasking CTD kinases for the new millenium
    Greenleaf, Arno L.
    TRANSCRIPTION-AUSTIN, 2019, 10 (02): : 91 - 110
  • [48] Targeting MYC dependency in ovarian cancer through inhibition of CDK7 and CDK12/13
    Zeng, Mei
    Kwiatkowski, Nicholas P.
    Zhang, Tinghu
    Nabet, Behnam
    Xu, Mousheng
    Liang, Yanke
    Quan, Chunshan
    Wang, Jinhua
    Hao, Mingfeng
    Palakurthi, Sangeetha
    Zhou, Shan
    Zeng, Qing
    Kirschmeier, Paul T.
    Meghani, Khyati
    Leggett, Alan L.
    Qi, Jun
    Shapiro, Geoffrey I.
    Liu, Joyce F.
    Matulonis, Ursula A.
    Lin, Charles Y.
    Konstantinopoulos, Panagiotis A.
    Gray, Nathanael S.
    ELIFE, 2018, 7
  • [49] A Splice Site Variant of CDK12 and Breast Cancer in Three Eurasian Populations
    Bogdanova, Natalia, V
    Schuermann, Peter
    Valova, Yana
    Dubrowinskaja, Natalia
    Turmanov, Nurzhan
    Yugay, Tatyana
    Essimsiitova, Zura
    Mingazheva, Elvira
    Prokofyeva, Darya
    Bermisheva, Marina
    Khusnutdinova, Elza
    Doerk, Thilo
    FRONTIERS IN ONCOLOGY, 2019, 9
  • [50] Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer
    Wu, Yi-Mi
    Cieslik, Marcin
    Lonigro, Robert J.
    Vats, Pankaj
    Reimers, Melissa A.
    Cao, Xuhong
    Ning, Yu
    Wang, Lisha
    Kunju, Lakshmi P.
    de Sarkar, Navonil
    Heath, Elisabeth I.
    Chou, Jonathan
    Feng, Felix Y.
    Nelson, Peter S.
    de Bono, Johann S.
    Zou, Weiping
    Montgomery, Bruce
    Alva, Ajjai
    Robinson, Dan R.
    Chinnaiyan, Arul M.
    CELL, 2018, 173 (07) : 1770 - +